Oxidative stress is an important contributor to the pathophysiology of sickle cell disease. The pathways involved are complex and interlinked. L-glutamine is an amino acid with myriad roles in the body, including the synthesis of antioxidants, such as reduced glutathione and the cofactors NAD(H) and NADP(H), as well as nitric oxide—so it has therapeutic potential as an antioxidant. However, the relative impact of L-glutamine on the redox environment in red blood cells in sickle cell disease is not fully understood, and there are few therapeutic trials in sickle cell disease. Following the FDA approval of L-glutamine for sickle cell disease, more research is still needed to understand its clinical effects and role in therapy.
Impact statement
L-glutamine has been recently approved by the FDA for the prevention of acute complications in sickle cell disease (SCD). However, there are many gaps in our understanding of the biologic role of glutamine and its therapeutic implications in SCD. This review summarizes the pre-clinical and clinical evidence that can inform clinical decision-making and future research on glutamine therapy in SCD patients.
NurEBiemondBJOttenHMBrandjesDPSchnogJJGroupCS.Oxidative stress in sickle cell disease: pathophysiology and potential implications for disease management. Am J Hematol2011;
86:484–9
2.
GoodmanSR.The irreversibly sickled cell: a perspective. Cell Mol Biol2004;
50:53–8
3.
AslanMThornley-BrownDFreemanBA.Reactive species in sickle cell disease. Ann N Y Acad Sci2000;
899:375–91
AmerJGhotiHRachmilewitzEKorenALevinCFibachE.Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol2006;
132:108–13
6.
CruzatVMacedo RogeroMNoel KeaneKCuriRNewsholmeP.Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients2018;
10:1564
7.
SalmanEKHaymondMWBayneESagerBKWiisanenAPitelPDarmaunD.Protein and energy metabolism in prepubertal children with sickle cell anemia. Pediatr Res1996;
40:34–40
8.
QuinnCT.l-Glutamine for sickle cell anemia: more questions than answers. Blood2018;
132:689–93
9.
NiiharaYMh EckmanJRKohHCooperMLZieglerTRRazonRTanakaKRStarkCWJohnsonCS.L-Glutamine therapy reduces hospitalization for sickle cell anemia and sickle β°-thalassemia patients at six months – a phase II randomized trial. Clin Pharmacol Biopharm2014;
3:116
10.
NiiharaYMillerSTKanterJLanzkronSSmithWRHsuLLGordeukVRViswanathanKSarnaikSOsunkwoIGuillaumeESadanandanSSiegerLLaskyJLPanosyanEHBlakeOANewTNBellevueRTranLTRazonRLStarkCWNeumayrLDVichinskyEP.Disease IotPTol-GiSC. A phase 3 trial of l-Glutamine in sickle cell disease. N Engl J Med2018;
379:226–35
11.
SchaferFQBuettnerGR.Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med2001;
30:1191–212
12.
GarelMCDomengetCCaburi-MartinJPrehuCGalacterosFBeuzardY.Covalent binding of glutathione to hemoglobin. I. Inhibition of hemoglobin S polymerization. J Biol Chem1986;
261:14704–9
13.
GriffithOW.Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med1999;
27:922–35
14.
NurEVerwijsMde WaartDRSchnogJJOttenHMBrandjesDPBiemondBJElferinkRPGroupCS.Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes. Biochim Biophys Acta2011;
1812:1412–7
15.
TatumVLChowCK.Antioxidant status and susceptibility of sickle erythrocytes to oxidative and osmotic stress. Free Radic Res1996;
25:133–9
16.
ChanACChowCKChiuD.Interaction of antioxidants and their implication in genetic anemia. Proc Soc Exp Biol Med1999;
222:274–82
17.
GiziAPapassotiriouIApostolakouFLazaropoulouCPapastamatakiMKanavakiIKalotychouVGoussetisEKattamisARombosIKanavakisE.Assessment of oxidative stress in patients with sickle cell disease: the glutathione system and the oxidant-antioxidant status. Blood Cells Mol Dis2011;
46:220–5
18.
ReidMBadalooAForresterTJahoorF.In vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease. Am J Physiol Endocrinol Metab2006;
291:E73–9
19.
RaftosJEWhillierSKuchelPW.Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data. J Biol Chem2010;
285:23557–67
20.
ElloryJCPrestonRLOsotimehinBYoungJD.Transport of amino acids for glutathione biosynthesis in human and dog red cells. Biomed Biochim Acta1983;
42:S48–52
21.
NiiharaYZerezCRAkiyamaDSTanakaKR.Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J Lab Clin Med1997;
130:83–90
22.
EllingerJJLewisIAMarkleyJL.Role of aminotransferases in glutamate metabolism of human erythrocytes. J Biomol NMR2011;
49:221–9
23.
WhillierSGarciaBChapmanBEKuchelPWRaftosJE.Glutamine and α-ketoglutarate as glutamate sources for glutathione synthesis in human erythrocytes. FEBS J2011;
278:3152–63
24.
KiesslingKRobertsNGibsonJSElloryJC.A comparison in normal individuals and sickle cell patients of reduced glutathione precursors and their transport between plasma and red cells. Hematol J2000;
1:243–9
25.
MorrisCRSuhJHHagarWLarkinSBlandDASteinbergMHVichinskyEPShigenagaMAmesBKuypersFAKlingsES.Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood2008;
111:402–10
26.
BadalooAReidMForresterTHeirdWCJahoorF.Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr2002;
76:646–52
27.
LyonsJRauh-PfeifferAYuYMLuXMZurakowskiDTompkinsRGAjamiAMYoungVRCastilloL.Blood glutathione synthesis rates in healthy adults receiving a sulfur amino acid-free diet. Proc Natl Acad Sci U S A2000;
97:5071–6
28.
ShengKShariffMHebbelRP.Comparative oxidation of hemoglobins A and S. Blood1998;
91:3467–70
29.
RepkaTHebbelRP.Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood1991;
78:2753–8
ScottMDZuoLLubinBHChiuDT.NADPH, not glutathione, status modulates oxidant sensitivity in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. Blood1991;
77:2059–64
32.
GaetaniGFGalianoSCanepaLFerrarisAMKirkmanHN.Catalase and glutathione peroxidase are equally active in detoxification of hydrogen peroxide in human erythrocytes. Blood1989;
73:334–9
33.
ZerezCRLachantNALeeSJTanakaKR.Decreased erythrocyte nicotinamide adenine dinucleotide redox potential and abnormal pyridine nucleotide content in sickle cell disease. Blood1988;
71:512–5
34.
ZerezCRWongMDTanakaKR.Partial purification and properties of nicotinamide adenine dinucleotide synthetase from human erythrocytes: evidence that enzyme activity is a sensitive indicator of lead exposure. Blood1990;
75:1576–82
35.
NiiharaYZerezCRAkiyamaDSTanakaKR.Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol1998;
58:117–21
36.
MarçalLEDias-da-MottaPMRehderJMamoniRLBlottaMHWhitneyCBNewburgerPECostaFFSaadSTCondino-NetoA.Up-regulation of NADPH oxidase components and increased production of interferon-gamma by leukocytes from sickle cell disease patients. Am J Hematol2008;
83:41–5
37.
GeorgeAPushkaranSKonstantinidisDGKoochakiSMalikPMohandasNZhengYJoinerCHKalfaTA.Erythrocyte NADPH oxidase activity modulated by rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood2013;
121:2099–107
BoelensPGMelisGCvan LeeuwenPAten HaveGADeutzNE.Route of administration (enteral or parenteral) affects the contribution of L-glutamine to de novo L-arginine synthesis in mice: a stable-isotope study. Am J Physiol Endocrinol Metab2006;
291:E683–90
40.
Ligthart-MelisGCvan de PollMCBoelensPGDejongCHDeutzNEvan LeeuwenPA.Glutamine is an important precursor for de novo synthesis of arginine in humans. Am J Clin Nutr2008;
87:1282–9
41.
CastilloLBeaumierLAjamiAMYoungVR.Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling. Proc Natl Acad Sci U S A1996;
93:11460–5
42.
MackAKKatoGJ.Sickle cell disease and nitric oxide: a paradigm shift?Int J Biochem Cell Biol2006;
38:1237–43
43.
WinkDMirandaKEspeyMPlutaRHewettSColtonCVitekMFeelischMGrishamM.Mechanisms of the antioxidant effects of nitric oxide. Antioxid Redox Signal2001;
3:203–13
MorrisCRVichinskyEPvan WarmerdamJMachadoLKepka-LenhartDMorrisSMKuypersFA.Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol2003;
25:629–34
46.
MorrisCRKatoGJPoljakovicMWangXBlackwelderWCSachdevVHazenSLVichinskyEPMorrisSMGladwinMT.Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA2005;
294:81–90
47.
MorrisCRKuypersFHagarRWAnsariMLarkinSKLavrishaLWardlawMZhouAVichinskyESuhJH.Metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: preliminary pharmacokinetics results. Blood2010;
116:1636
48.
NiiharaYMatsuiNMShenYMAkiyamaDAJohnsonCSSungaMAMagpayoJEmburySHKalraVKHo ChoSTanakaKR.L-Glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord2005;
5:4
49.
NewsholmeP.Why is L-glutamine metabolism important to cells of the immune system in health, postinjury. Surgery or infection? J Nutr2001;
131:2515S–22S; discussion 23S–4S
50.
Pithon-CuriTCLevadaACLopesLRDoiSQCuriGlutamine plays a role in superoxide production and the expression of p47phox, p22phox and gp91phox in rat neutrophils. Clin Sci2002;
103:403–8 R.
51.
CalderPCYaqoobP.Glutamine and the immune system. Amino Acids1999;
17:227–41
52.
DuranteW.The emerging role of l-Glutamine in cardiovascular health and disease. Nutrients2019;
11:pii: E2092
53.
PiaoLFangYHParikhKRyanJJTothPTArcherSL.Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med2013;
91:1185–97
54.
MatthewsDEMaranoMACampbellRG.Splanchnic bed utilization of glutamine and glutamic acid in humans. Am J Physiol1993;
264:E848–54
55.
HankardRGDarmaunDSagerBKD'AmoreDParsonsWRHaymondM.Response of glutamine metabolism to exogenous glutamine in humans. Am J Physiol1995;
269:E663–70
56.
ZieglerTRBenfellKSmithRJYoungLSBrownEFerrari-BalivieraELoweDKWilmoreDW.Safety and metabolic effects of L-glutamine administration in humans. JPEN J Parenter Enteral Nutr1990;
14:137S–46S
AdibiSA.Regulation of expression of the intestinal oligopeptide transporter (pept-1) in health and disease. Am J Physiol Gastrointest Liver Physiol2003;
285:G779–88
59.
MorrisCRHamilton-ReevesJMartindaleRGSaravMOchoa GautierJB.Acquired amino acid deficiencies: a focus on arginine and glutamine. Nutr Clin Pract2017;
32:30S–47S
60.
Ramezani AhmadiARayyaniEBahreiniMMansooriA.The effect of glutamine supplementation on athletic performance, body composition, and immune function: a systematic review and a Meta-analysis of clinical trials. Clin Nutr2019;
38:1076–91
61.
WalesPWNasrAde SilvaNYamadaJ.Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev2010;
6:CD006321
62.
ZieglerTRMayAKHebbarGEasleyKAGriffithDPDaveNCollierBRCotsonisGAHaoLLeongTManatungaAKRosenbergESJonesDPMartinGSJensenGLSaxHCKudskKAGallowayJRBlumbergHMEvansMEWischmeyerPE.Efficacy and safety of glutamine-supplemented parenteral nutrition in surgical ICU patients: an American multicenter randomized controlled trial. Ann Surg2016;
263:646–55
63.
NovakFHeylandDKAvenellADroverJWSuX.Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med2002;
30:2022–9
64.
ManzanaresWDhaliwalRJiangXMurchLHeylandDK.Antioxidant micronutrients in the critically ill: a systematic review and Meta-analysis. Crit Care2012;
16: R66
65.
HeylandDMuscedereJWischmeyerPECookDJonesGAlbertMElkeGBergerMMDayAGGroupC.A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med2013;
368:1489–97
66.
BistrianBR.Glutamine and antioxidants in critically ill patients. N Engl J Med2013;
369:482–85
ChengSRheeEPLarsonMGLewisGDMcCabeELShenDPalmaMJRobertsLDDejamASouzaALDeikAAMagnussonMFoxCSO'DonnellCJVasanRSMelanderOClishCBGersztenREWangTJ.Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation2012;
125:2222–31
69.
Guasch-FerréMHrubyAToledoEClishCBMartínez-GonzálezMASalas-SalvadóJHuFB.Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care2016;
39:833–46
70.
GreenfieldJRFarooqiISKeoghJMHenningEHabibAMBlackwoodAReimannFHolstJJGribbleFM.Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr2009;
89:106–13
71.
MansourAMohajeri-TehraniMRQorbaniMHeshmatRLarijaniBHosseiniS.Effect of glutamine supplementation on cardiovascular risk factors in patients with type 2 diabetes. Nutrition2015;
31:119–26
72.
MaWHeianzaYHuangTWangTSunDZhengYHuFBRexrodeKMMansonJEQiL.Dietary glutamine, glutamate and mortality: two large prospective studies in US men and women. Int J Epidemiol2018;
47:311–20
73.
WardESmithMHendersonMReidULewisIKinseySAllgarVBowersDPictonSV.The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr2009;
63:134–40
74.
WardEPictonSReidUThomasDGardenerCSmithMHendersonMHoldenVKinseySLewisIAllgarV.Oral glutamine in paediatric oncology patients: a dose finding study. Eur J Clin Nutr2003;
57:31–6
75.
SkubitzKMAndersonPM.Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med1996;
127:223–8
76.
JebbSAOsborneRJMaughanTSMohideenNMackPMortDShelleyMDEliaM.5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer1994;
70:732–5
77.
JebbSAMarcusREliaM.A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clin Nutr1995;
14:162–5
78.
SchloerbPRSkikneBS.Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr1999;
23:117–22
79.
ZieglerTRYoungLSBenfellKScheltingaMHortosKByeRMorrowFDJacobsDOSmithRJAntinJH.Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med1992;
116:821–8
80.
WilliamsROliviSLiCSStormMCremerLMackertPWangW.Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol2004;
26:619–25
81.
BachmannC.Mechanisms of hyperammonemia. Clin Chem Lab Med2002;
40:653–62
MinnitiCP.l-Glutamine and the dawn of combination therapy for sickle cell disease. N Engl J Med2018;
379:292–94
84.
L-glutamine (Endari) for sickle cell disease. Med Lett Drugs Ther2018;
60:21–2
85.
WalshKECutronaSLKavanaghPLCrosbyLEMaloneCLobnerKBundyDG.Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics2014;
134:1175–83
86.
BrandowAMPanepintoJA.Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol2010;
3:255–60
